0.001 s

- (-%)
Range - - -   (-%)
Open -
Previous Close 0.001
Buy Price -
Buy Volume -
Sell Price -
Sell Volume -
Volume -
Value -
Remark s
Measurement Type Value
EPS (USD) -0.197
Trailing EPS (USD) 0.001
NAV (USD) -0.08
Cash In Hand (USD) 0.123
Dividend -
Dividend Yield (%) -
PE -
Trailing PE 163.289
Price / NAV -2.247
Price / Cash In Hand 1.46
Issued & Paid-up Shares 33,572,000
Treasury Shares -
Market Cap (M) 6.205
Par Value (USD) n.a.
Beta - 75 Days 4.259
R-Squared - 75 Days(%) 35.79
Beta - 500 Days 1.742
R-Squared - 500 Days(%) 8.95
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 30 Sep 2021 02:51.
Data powered by
View All Events


Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.